Diagnostic value of a nanopore sequencing assay of bronchoalveolar lavage fluid in pulmonary tuberculosis
- PMID: 36890507
- PMCID: PMC9996878
- DOI: 10.1186/s12890-023-02337-3
Diagnostic value of a nanopore sequencing assay of bronchoalveolar lavage fluid in pulmonary tuberculosis
Abstract
Background: To determine the diagnostic accuracy of a nanopore sequencing assay of PCR products from a M. tuberculosis complex-specific region for testing of bronchoalveolar lavage fluid (BALF) samples or sputum samples from suspected pulmonary tuberculosis (PTB) patients and compare the results to results obtained for MGIT and Xpert assays.
Methods: Cases with suspected PTB (n = 55) were diagnosed from January 2019 to December 2021 based on results of nanopore sequencing, MGIT culture, and Xpert MTB/RIF testing of BALF and sputum samples collected during hospitalization. Diagnostic accuracies of assays were compared.
Results: Ultimately, data from 29 PTB patients and 26 non-PTB cases were analyzed. PTB diagnostic sensitivities of MGIT, Xpert MTB/RIF, and nanopore sequencing assays were 48.28%, 41.38%, and 75.86%, respectively, thus demonstrating that nanopore sequencing provided greater sensitivity than was provided by MGIT culture and Xpert assays (P < 0.05). PTB diagnostic specificities of the respective assays were 65.38%, 100%, and 80.77%, which corresponded with kappa coefficient (κ) values of 0.14, 0.40, and 0.56, respectively. These results indicate that nanopore sequencing provided superior overall performance as compared to Xpert and MGIT culture assays and provided significantly greater PTB diagnostic accuracy than Xpert and sensitivity comparable to that of the MGIT culture assay.
Conclusion: Our findings suggest that improved detection of PTB in suspected cases was achieved using nanopore sequencing-based testing of BALF or sputum samples than was achieved using Xpert and MGIT culture-based assays, and nanopore sequencing results alone cannot be used to rule out PTB.
Keywords: Nanopore sequencing assay; Pulmonary tuberculosis; Sensitivity; Specificity.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Nanopore sequencing for smear-negative pulmonary tuberculosis-a multicentre prospective study in China.Ann Clin Microbiol Antimicrob. 2024 Jun 14;23(1):51. doi: 10.1186/s12941-024-00714-2. Ann Clin Microbiol Antimicrob. 2024. PMID: 38877520 Free PMC article.
-
Determination of the diagnostic accuracy of nanopore sequencing using bronchoalveolar lavage fluid samples from patients with sputum-scarce pulmonary tuberculosis.J Infect Chemother. 2024 Feb;30(2):98-103. doi: 10.1016/j.jiac.2023.09.014. Epub 2023 Sep 14. J Infect Chemother. 2024. PMID: 37714266
-
A preliminary evaluation of targeted nanopore sequencing technology for the detection of Mycobacterium tuberculosis in bronchoalveolar lavage fluid specimens.Front Cell Infect Microbiol. 2023 Nov 10;13:1107990. doi: 10.3389/fcimb.2023.1107990. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 38029234 Free PMC article.
-
Which sample type is better for Xpert MTB/RIF to diagnose adult and pediatric pulmonary tuberculosis?Biosci Rep. 2020 Aug 28;40(8):BSR20200308. doi: 10.1042/BSR20200308. Biosci Rep. 2020. PMID: 32701147 Free PMC article.
-
Evaluation of the diagnostic efficiency of fluorescence in situ hybridization for pulmonary tuberculosis: a systematic review and meta-analysis.Front Med (Lausanne). 2025 Jan 6;11:1467530. doi: 10.3389/fmed.2024.1467530. eCollection 2024. Front Med (Lausanne). 2025. PMID: 39835097 Free PMC article.
Cited by
-
Enhanced diagnosis of pulmonary tuberculosis through nucleotide MALDI-TOF MS analysis of BALF: a retrospective clinical study.Sci Rep. 2024 Aug 8;14(1):18416. doi: 10.1038/s41598-024-66178-8. Sci Rep. 2024. PMID: 39117658 Free PMC article.
-
Diagnostic value of nanopore sequencing technology in nontuberculous mycobacterial pulmonary disease.Am J Transl Res. 2024 Aug 15;16(8):4208-4215. doi: 10.62347/HHRH8076. eCollection 2024. Am J Transl Res. 2024. PMID: 39262756 Free PMC article.
-
Evaluation of Nanopore Sequencing for Diagnosing Pulmonary Tuberculosis Using Negative Smear Clinical Specimens.Infect Drug Resist. 2024 Feb 19;17:673-682. doi: 10.2147/IDR.S442229. eCollection 2024. Infect Drug Resist. 2024. PMID: 38405053 Free PMC article.
-
Diagnostic accuracy of nanopore sequencing for detecting Mycobacterium tuberculosis and drug-resistant strains: a systematic review and meta-analysis.Sci Rep. 2025 Apr 4;15(1):11626. doi: 10.1038/s41598-025-90089-x. Sci Rep. 2025. PMID: 40185766 Free PMC article.
-
The positivity rates and drug resistance patterns of Mycobacterium tuberculosis using nucleotide MALDI-TOF MS assay among suspected tuberculosis patients in Shandong, China: a multi-center prospective study.Front Public Health. 2024 Jan 18;12:1322426. doi: 10.3389/fpubh.2024.1322426. eCollection 2024. Front Public Health. 2024. PMID: 38304182 Free PMC article.
References
-
- World Health Organization . Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
-
- WHO . Policy update: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Geneva: World Health Organization; 2015. - PubMed
-
- Gliddon HD, Frampton D, Munsamy V, Heaney J, Pataillot-Meakin T, Nastouli E, et al. A rapid drug resistance genotyping workflow for Mycobacterium tuberculosis, using targeted isothermal amplification and nanopore sequencing. Microbiol Spectr. 2021;9:e0061021. doi: 10.1128/Spectrum.00610-21. - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources